{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:20:41Z","timestamp":1794651641499,"version":"4.9.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute myeloid leukemia (AML) cases with 11q23 abnormalities involving the MLL gene comprise one category of recurring genetic abnormalities in the WHO classification. In an unselected series of 1897 AML cases, 54 patients with an 11q23\/MLL rearrangement were identified, resulting in an incidence of 2.8%. The incidence of AML with MLL rearrangement was significantly higher in therapy-related AML (t-AML) than in de novo AML (9.4% vs 2.6%, P &amp;lt; .0001). The frequency of MLL rearrangements was significantly higher in patients younger than 60 years (5.3% vs 0.8%, P &amp;lt; .0001). While the incidence of MLL rearrangements in AML M4, M5a, and M5b was 4.7%, 33.3%, and 15.9%, respectively, it was found in only 0.9% of all other French-American-British (FAB) subtypes (P &amp;lt; .0001). Compared with AML with intermediate karyotype, AML with 11q23\/MLL rearrangement had a worse outcome, which was rather comparable with AML with unfavorable karyotype. Compared with t-AML, the median overall survival (OS) of de novo AML with MLL rearrangement was significantly better (2.5 vs 10 months, P = .0143). No significant differences in median OS were observed between cases with t(9;11) compared with all other MLL rearrangements (10.0 vs 8.9 months, P = .36). In conclusion, the category AML with 11q23\/MLL abnormalities accounts for 2.8% of unselected AML, is closely associated with monocytic differentiation, and has a dismal prognosis. (Blood. 2003;102:2395-2402)<\/jats:p>","DOI":"10.1182\/blood-2003-02-0434","type":"journal-article","created":{"date-parts":[[2003,6,16]],"date-time":"2003-06-16T20:34:45Z","timestamp":1055795685000},"page":"2395-2402","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":300,"title":["AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases"],"prefix":"10.1182","volume":"102","author":[{"given":"Claudia","family":"Schoch","sequence":"first","affiliation":[{"name":"From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schnittger","sequence":"additional","affiliation":[{"name":"From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Klaus","sequence":"additional","affiliation":[{"name":"From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[{"name":"From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222284058700_REF1","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33: 451-458.","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"2020021222284058700_REF2","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103: 620-625.","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"2020021222284058700_REF3","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol. 1991;78: 325-329.","DOI":"10.1111\/j.1365-2141.1991.tb04444.x"},{"key":"2020021222284058700_REF4","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med. 1985;103: 460-462.","DOI":"10.7326\/0003-4819-103-3-460"},{"key":"2020021222284058700_REF5","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol. 1980;44: 169-170.","DOI":"10.1111\/j.1365-2141.1980.tb01195.x"},{"key":"2020021222284058700_REF6","doi-asserted-by":"crossref","unstructured":"Second MIC Cooperative Study Group. Morpholoic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. Cancer Genet Cytogenet. 1988;30: 1-15.","DOI":"10.1016\/0165-4608(88)90087-8"},{"key":"2020021222284058700_REF7","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissue: report of the clinical advisory committee meeting \u2014 Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"2020021222284058700_REF8","unstructured":"Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman J, eds. World Health Organization of Tumors, Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 75-108."},{"key":"2020021222284058700_REF9","unstructured":"Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol. 1999;36(suppl 7): 59-72."},{"key":"2020021222284058700_REF10","unstructured":"Huret JL. 11q23 rearrangements in leukaemia. Atlas Cytogenet Oncol Haematol. January 2001. Available at: http:\/\/www.infobiogen.fr\/services\/chromcancer\/Anomalies\/11q23ID1030.html."},{"key":"2020021222284058700_REF11","doi-asserted-by":"crossref","unstructured":"Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major dependent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood. 2003;101: 64-70.","DOI":"10.1182\/blood-2002-02-0532"},{"key":"2020021222284058700_REF12","doi-asserted-by":"crossref","unstructured":"Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia. 2000;14: 1362-1370.","DOI":"10.1038\/sj.leu.2401843"},{"key":"2020021222284058700_REF13","unstructured":"ISCN (1995): Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature. Mitelman F, ed. Basel, Switzerland: S. Karger; 1995."},{"key":"2020021222284058700_REF14","doi-asserted-by":"crossref","unstructured":"Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16: 53-59.","DOI":"10.1038\/sj.leu.2402329"},{"key":"2020021222284058700_REF15","unstructured":"Repp R, Borkhardt A, Haupt E, et al. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis. Leukemia. 1995;9: 210-215."},{"key":"2020021222284058700_REF16","doi-asserted-by":"crossref","unstructured":"Prasad R, Leshkowitz D, Gu Y, et al. Leucinezipper dimerization motif encoded by the AF17 gene fused to ALL-1 (MLL) in acute leukemia. Proc Natl Acad Sci U S A. 1994;91: 8107-8111.","DOI":"10.1073\/pnas.91.17.8107"},{"key":"2020021222284058700_REF17","doi-asserted-by":"crossref","unstructured":"Rubnitz JE, Behm FG, Curcio-Brint AM, et al. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood. 1996;87: 4804-4808.","DOI":"10.1182\/blood.V87.11.4804.bloodjournal87114804"},{"key":"2020021222284058700_REF18","doi-asserted-by":"crossref","unstructured":"Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood. 1995;85: 650-656.","DOI":"10.1182\/blood.V85.3.650.bloodjournal853650"},{"key":"2020021222284058700_REF19","doi-asserted-by":"crossref","unstructured":"Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subytpe, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100: 159-166.","DOI":"10.1182\/blood.V100.1.59"},{"key":"2020021222284058700_REF20","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 456-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021222284058700_REF21","doi-asserted-by":"crossref","unstructured":"Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977;35: 1-39.","DOI":"10.1038\/bjc.1977.1"},{"key":"2020021222284058700_REF22","doi-asserted-by":"crossref","unstructured":"Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM, on behalf of the European 11q23 Workshop. Hematological malignancies with t(9;11)(p21-22;q23)\u2014a laboratory and clinical study of 125 cases. Leukemia. 1998;12: 792-800.","DOI":"10.1038\/sj.leu.2401014"},{"key":"2020021222284058700_REF23","doi-asserted-by":"crossref","unstructured":"Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20: 2302-2309.","DOI":"10.1200\/JCO.2002.08.023"},{"key":"2020021222284058700_REF24","doi-asserted-by":"crossref","unstructured":"Bloomfield CD, Archer KJ, Mro\u0301zek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an International Workshop. Genes Chromosomes Cancer. 2002;33: 362-378.","DOI":"10.1002\/gcc.10046"},{"key":"2020021222284058700_REF25","doi-asserted-by":"crossref","unstructured":"Mro\u0301zek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997;90: 4532-4538.","DOI":"10.1182\/blood.V90.11.4532"},{"key":"2020021222284058700_REF26","unstructured":"Johansson B, Mertens F, Mitelman F. Secondary chromosomal abnormalities in acute leukemias. Leukemia. 1994;8: 953-962."},{"key":"2020021222284058700_REF27","doi-asserted-by":"crossref","unstructured":"Byrd JC, Mro\u0301zek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100: 4325-4336.","DOI":"10.1182\/blood-2002-03-0772"},{"key":"2020021222284058700_REF28","doi-asserted-by":"crossref","unstructured":"Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92: 2322-2333.","DOI":"10.1182\/blood.V92.7.2322"},{"key":"2020021222284058700_REF29","doi-asserted-by":"crossref","unstructured":"Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood. 2001;98: 1312-1320.","DOI":"10.1182\/blood.V98.5.1312"},{"key":"2020021222284058700_REF30","doi-asserted-by":"crossref","unstructured":"Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study. Blood. 2000;96: 4075-4083.","DOI":"10.1182\/blood.V96.13.4075"},{"key":"2020021222284058700_REF31","doi-asserted-by":"crossref","unstructured":"Lillington DM, Young BD, Berger R, et al. The t(10;11)(p12;q23) translocation in acute leukaemia: a cytogenetic and clinical study on 20 patients. Leukemia. 1998;12: 801-804.","DOI":"10.1038\/sj.leu.2401015"},{"key":"2020021222284058700_REF32","doi-asserted-by":"crossref","unstructured":"Van Limbergen H, Poppe B, Janssens A, et al. Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia. Leukemia. 2002;16: 344-351.","DOI":"10.1038\/sj.leu.2402397"},{"key":"2020021222284058700_REF33","unstructured":"Giugliano E, Rege-Cambrin G, Scaravaglio P, et al. Two new translocations involving the 11q23 region map outside the MLL locus in myeloid leukemias. Haematologica. 2002;87: 1014-1020."},{"key":"2020021222284058700_REF34","doi-asserted-by":"crossref","unstructured":"Archimbaud E, Charrin C, Magaud J-P, et al. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint. Leukemia. 1998;12: 25-33.","DOI":"10.1038\/sj.leu.2400853"},{"key":"2020021222284058700_REF35","unstructured":"Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a Cooperative Pediatric Oncology Group Study-POG 8821. Blood. 1999;94: 3707-3716."},{"key":"2020021222284058700_REF36","doi-asserted-by":"crossref","unstructured":"Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients &lt; 46 years old with acute myeloid leukemia (AML) in first complete remission (CR1): an intention to treat analysis of the EORTC\/GIMEMA AML-10 trial. Blood. Pre-published on April 24, 2003, as DOI 10.1182\/blood-2002-12-3714.","DOI":"10.1182\/blood-2002-12-3714"},{"key":"2020021222284058700_REF37","doi-asserted-by":"crossref","unstructured":"Yeoh E-J, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1: 133-143.","DOI":"10.1016\/S1535-6108(02)00032-6"},{"key":"2020021222284058700_REF38","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30: 41-47.","DOI":"10.1038\/ng765"},{"key":"2020021222284058700_REF39","unstructured":"Kohlmann A, Schoch C, Dugas M, et al. Gene expression profiles of t(11q23)\/MLL positive ALL and AML [abstract]. Blood. 2002;100: 84a."},{"key":"2020021222284058700_REF40","unstructured":"Haferlach T, Kohlmann A, Dugas M, et al. The diagnosis of 14 specific subtypes of leukemia is possible based on gene expression profiles: a study on 263 patients with AML, ALL, CML, or CLL [abstract]. Blood. 2002;100: 139a."},{"key":"2020021222284058700_REF41","unstructured":"Schnittger S, Schoch C, Dugas M, Haferlach T, Hiddemann W. Partial tandem duplication (PTD) of the MLL gene: a study of 1603 patients reveals high frequency in secondary acute myeloid leukemia and low association with trisomy 11 [abstract]. Blood. 2001;98: 801a."},{"key":"2020021222284058700_REF42","unstructured":"Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56: 1418-1425."},{"key":"2020021222284058700_REF43","unstructured":"Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58: 55-59."},{"key":"2020021222284058700_REF44","doi-asserted-by":"crossref","unstructured":"Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol. 1999;78: 251-264.","DOI":"10.1007\/s002770050511"},{"key":"2020021222284058700_REF45","doi-asserted-by":"crossref","unstructured":"Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14: 796-804.","DOI":"10.1038\/sj.leu.2401773"},{"key":"2020021222284058700_REF46","unstructured":"Schnittger S, Kohlmann A, Haferlach T, et al. Acute myeloid leukemia (AML) with partial tandem duplication of the MLL gene (MLL-PTD) can be discriminated from MLL translocations based on specific gene expression profiles [abstract]. Blood. 2002;100: 310a."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/7\/2395\/1691177\/h81903002395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/7\/2395\/1691177\/h81903002395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:29:01Z","timestamp":1581546541000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/7\/2395\/17953\/AML-with-11q23MLL-abnormalities-as-defined-by-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-02-0434","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}